BiotechTube

Elironrasib + Daraxonrasib

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Small Cell Lung Cancer (NSCLC)

Conditions

Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

Trial Timeline

Nov 14, 2023 → Jun 1, 2029

NCT ID
NCT06128551

About Elironrasib + Daraxonrasib

Elironrasib + Daraxonrasib is a phase 1/2 stage product being developed by REVOLUTION Medicines for Non-Small Cell Lung Cancer (NSCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06128551. Target conditions include Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06128551Phase 1/2Recruiting

Competing Products

20 competing products in Non-Small Cell Lung Cancer (NSCLC)

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3NanobiotixPhase 1/2
36
pemetrexed + erlotinibEli LillyPhase 2
52
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
pemetrexed + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
pemetrexed + docetaxelEli LillyPhase 3
77
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
52
PemCarbo + Pem onlyEli LillyPhase 3
77
LY2875358 + ErlotinibEli LillyPhase 2
52
AdjuvantInsight Molecular DiagnosticsPre-clinical
15
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
77
Enzastaurin HCLEli LillyPhase 2
52
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 2
44
pemetrexed + gemcitabineEli LillyPhase 2
52
ALIMTA + CarboplatinEli LillyPhase 2
52
Tomivosertib + Pembrolizumab + PemetrexedeFFECTOR TherapeuticsPhase 2
44
Divarasib + Pembrolizumab + Pemetrexed + Carboplatin + CisplatinChugai PharmaceuticalPhase 3
77

Other Products from REVOLUTION Medicines

daraxonrasibPhase 3
74
daraxonrasib + docetaxelPhase 3
74
RMC-6236 + Gemcitabine + nab-paclitaxel + Irinotecan + Liposomal irinotecan + 5-fluorouracil + leucovorin + OxaliplatinPhase 3
74
RMC-6291 + RMC-6236 + Pembrolizumab + Cisplatin + Carboplatin + Pemetrexed + RMC-9805Phase 1/2
38
TNG462 + RMC-9805 + RMC-6236 + mFOLFIRINOX + gemcitabine/nab-paclitaxelPhase 1/2
38